Rommer, Paulus S., Milo, Ron, Han, May H., Satyanarayan, Sammita, Sellner, Johann, Hauer, Larissa, Illes, Zsolt, Warnke, Clemens, Laurent, Sarah, Weber, Martin S., Zhang, Yinan and Stuve, Olaf (2019). Immunological Aspects of Approved MS Therapeutics. Front. Immunol., 10. LAUSANNE: FRONTIERS MEDIA SA. ISSN 1664-3224

Full text not available from this repository.

Abstract

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 1 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponimod, mitoxantrone, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, ocrelizumab, and natalizumab). Ocrelizumab was the first medication to be approved for primary progressive MS. The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS. Each agent's clinical development and potential side effects are discussed.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Rommer, Paulus S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Milo, RonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Han, May H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Satyanarayan, SammitaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sellner, JohannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hauer, LarissaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Illes, ZsoltUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Warnke, ClemensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Laurent, SarahUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weber, Martin S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zhang, YinanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stuve, OlafUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-135225
DOI: 10.3389/fimmu.2019.01564
Journal or Publication Title: Front. Immunol.
Volume: 10
Date: 2019
Publisher: FRONTIERS MEDIA SA
Place of Publication: LAUSANNE
ISSN: 1664-3224
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
REMITTING MULTIPLE-SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELEASE DIMETHYL FUMARATE; MYELIN BASIC-PROTEIN; LONG-TERM SAFETY; DISEASE-MODIFYING THERAPIES; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; SUBCUTANEOUS INTERFERON BETA-1A; GLATIRAMER ACETATE COPAXONE; PLACEBO-CONTROLLED PHASE-3Multiple languages
ImmunologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/13522

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item